Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Adenocarcinoma Clinical Trials

A listing of Adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (34) clinical trials

Single Arm Study of 6-Months Neoadjuvant ARN-509 Prior to Radical Prostatectomy

Study Drug Administration: If you are found to be eligible to take part in the study, you will take 4 tablets of apalutamide by mouth each day for a total of 24 weeks (about 6 months) leading up to your standard-of-care prostate surgery. You should take apalutamide at about the ...

Phase

ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer

PRIMARY OBJECTIVES: I. To determine the PSA >= 50% response rate (PSA50) from baseline using the Prostate Cancer Working Group 3 (PCWG3) criteria to pan-VEGFR/TIE2 tyrosine kinase inhibitor CEP-11981 (ESK981) as a single agent in men with castration-resistant prostate cancer (CRPC) who have progressed on enzalutamide (an oral androgen-receptor inhibitor) ...

Phase

Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance

PRIMARY OBJECTIVES: I. Determine the negative repeat biopsy rate by site directed and systematic prostate biopsy after 90-days of apalutamide. SECONDARY OBJECTIVES: I. Determine the rate of exit at 2 years from active surveillance due to pathologic reclassification. II. Determine the overall rate of exit at 2 years from active ...

Phase

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

PRIMARY OBJECTIVES: I. To test whether men with a poor initial response to androgen deprivation therapy (ADT) have a better front line therapeutic response to cabazitaxel as compared to historical controls of frontline metastatic castrate resistant prostate cancer (CRPC) therapy with abiraterone or enzalutamide. SECONDARY OBJECTIVES: I. To determine the ...

Phase

A Phase II Neoadjuvant Study of Apalutamide Abiraterone Acetate Prednisone Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

PRIMARY OBJECTIVES: I. The rate of the pathologic complete response (pCR) (i.e. no evidence of residual tumor) as assessed on prostatectomy specimens following 3-months (12 weeks) of neoadjuvant apalutamide, abiraterone acetate, degarelix and indomethacin. SECONDARY OBJECTIVES: I. To determine the negative margin rate as assessed on prostatectomy specimens following 3-months ...

Phase

Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer

Rationale: Hypofractionation with a stereotactic body radiotherapy (SBRT) technique for prostate cancer produces excellent treatment outcome in terms of survival and toxicity and is much more convenient than the current fractionation scheme. Local recurrence occurs most frequently at the site of the primary or dominant tumor location prior to treatment. ...

Phase

Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

Radiation therapy is an effective and frequently utilized modality for the treatment of clinically localized prostate cancer. Traditionally, external beam radiation has been delivered in a fractionated manner using daily doses of 1.8-2.0 Gy. This daily dose was derived from early animal experiments and clinical experience, supported by mathematical models ...

Phase

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

Enzalutamide is a second-generation androgen receptor signaling inhibitor that significantly prolongs survival in patients with metastatic castration-resistant prostate cancer who have received prior docetaxel chemotherapy 35,36. Enzalutamide has demonstrated activity in cells that overexpress the androgen receptor. Unlike previous androgen receptor blocker (ARB) agents, Enzalutamide does not display any agonist ...

Phase

Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound

The use of brachytherapy or implantation of radioactive sources into the prostate for adenocarcinoma has advantages over external beam radiation in that a very high dose can be delivered to the tumor while limiting the doses to the surrounding normal tissue (i.e., bowel and bladder). It is established that outcomes ...

Phase

C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

OBJECTIVES Determine the role of positron emission tomography using carbon-11 acetate (AC-PET) in the initial and subsequent management of patients with prostate cancer at intermediate or high risk for recurrence after initial curative therapy. Compare the value of AC-PET in predicting recurrence of prostate cancer with that of conventional approaches ...

Phase